Medtronic (NYSE:MDT) announced today that new data supports the use of its Symplicity Spyral renal denervation (RDN) system. As part of the medtech giant’s Spyral HTN global clinical program, three-year data from the Spyral HTN-ON MED and GSR-Define trials were presented at EuroPCR 2022 as late-breaking clinical trials demonstrating the benefit of the Symplicity blood […]
renal denervation
Medtronic releases new renal denervation results, closes trial enrollment
Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication. It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. […]
Some analysts are upbeat about Medtronic’s renal denervation prospects
Needham & Co. analysts are reiterating their Buy rating for Medtronic stock, saying that renal denervation (RDN) could still be a big opportunity for the medtech giant. Medtronic (NYSE:MDT) had to continue its Spyral HTN-ON MED trial into this year after failing to obtain the positive results needed to end enrollment early for the potential […]
MedtronicTalks: Why Symplicity Spyral trials are complicated, but worth it
Medtronic’s campaign to secure FDA approval of its renal denervation device — Symplicity Spyral — has been anything but simple. But in this episode of the MedtronicTalks podcast, Jason Weidman, SVP and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool […]
Medtronic builds suspense for renal denervation study results
Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference. The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar […]
Is renal denervation back as a high blood pressure treatment?
Medtronic (NYSE:MDT) today reported clinically significant and sustained blood pressure reduction among nearly 3,000 people with uncontrolled hypertension treated with the company’s Symplicity renal denervation system. The study results, reported today out of the 2021 EuroPCR Annual Meeting, come the same week as ReCor Medical touted its own positive renal denervation study at the American […]
ReCor Medical has positive renal denervation study news
ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, […]
Medtronic to test new ways to fine-tune renal denervation
As it continues to seek a renaissance in renal denervation, Medtronic (NYSE:MDT) plans to study how to better fine-tune the technology to treat hypertension. The world’s largest medical device company, run out of Fridley, Minn., announced Feb. 4 that it has started enrollment in a pilot study that will use the company’s Symplicity Spyral renal denervation […]
